Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Down 22.9% in March

by · The Cerbat Gem

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 226,000 shares, a decrease of 22.9% from the March 15th total of 293,200 shares. Based on an average trading volume of 1,520,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 2.9% of the company’s stock are sold short.

Cumberland Pharmaceuticals Stock Up 5.1 %

Shares of NASDAQ:CPIX traded up $0.23 during trading on Friday, hitting $4.76. 25,526 shares of the company were exchanged, compared to its average volume of 865,997. The firm’s 50 day moving average price is $4.87 and its 200-day moving average price is $2.95. Cumberland Pharmaceuticals has a 12-month low of $1.04 and a 12-month high of $7.25. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The stock has a market capitalization of $66.49 million, a P/E ratio of -6.18 and a beta of -0.24.

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%. The company had revenue of $10.44 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP lifted its holdings in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Free Report) by 94.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,649 shares of the specialty pharmaceutical company’s stock after acquiring an additional 18,271 shares during the period. Two Sigma Investments LP owned 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent reporting period. 15.51% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th.

Read Our Latest Stock Report on CPIX

Cumberland Pharmaceuticals Company Profile

(Get Free Report)

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

See Also